People with relapsing forms of multiple sclerosis (MS) have a new
option for reducing periodic attacks (relapses) and for delaying
the progression of MS-related disability. MS is typically treated
with injected drugs or infusions, which can be painful and
inconvenient and may discourage some patients from staying on
therapy. The FDA has approved the first oral medication,
fingolimod, brand name Gilenya.
To continue reading this article, you must login
Subscribe to Harvard Health Online for immediate access to health news and information from Harvard Medical School.